Background: Available evidence from animal studies suggests that branched-chain amino acids (BCAAs) may have a protective effect against colorectal carcinogenesis. However, a possible effect of BCAAs against colorectal neoplasia has not been evaluated in humans. Here, we aimed to evaluate whether plasma concentrations of BCAA are associated with the risk of colorectal adenoma (CRA), a precursor lesion of colorectal cancer.
Introduction
As the third most commonly diagnosed form of cancer and fourth most common cause of death from cancer globally, colorectal cancer (CRC) remains a target of considerable preventive efforts [1] . Several studies have associated dietary factors with risk of CRC and colorectal adenoma (CRA), including intake of meat and fish, grains/cereals and fruits and vegetables. Whereas these foods contain several bioactive compounds that could influence the likelihood of developing cancer through any of several pathways, they are also common dietary sources of branched-chain amino acids (BCAAs), whose role in carcinogenesis has not been fully explored. BCAAs, namely leucine, isoleucine and valine, are essential amino acids which account for 15%-25% of total dietary protein intake [2] . Unlike other amino acids, the BCAAs are catabolized in skeletal muscle, an important organ for the regulation of blood glucose [3] . Degradation of BCAAs, particularly leucine, has been linked to the stimulation of uptake and use of glucose by skeletal muscle via their role as a source of amino groups for alanine synthesis in the glucose-alanine cycle [2, 4] . Recently, isoleucine ingestion was also reported to reduce plasma levels of glucose by increasing muscle glucose uptake and whole-body glucose oxidation [5] , suggesting that these properties of BCAAs may have beneficial implications in glucose homeostasis. Indeed, a recent prospective study reported that high dietary BCAA intake was inversely associated with the risk of diabetes [6] .
Obesity and related metabolic complications, including insulin resistance and diabetes, are recognized risk factors for CRC. A recent experimental study in an obesity-related colon carcinogenesis model reported that dietary BCAA supplementation was associated with significant inhibition of the development of chemically induced colonic preneoplastic lesions, as well as a decrease in the concentration of markers of insulin resistance [7] . This inhibitory effect of BCAA on the development of colonic premalignancies was hypothesized to be due to an improvement in insulin resistance [7] . In addition, BCAA (isoleucine) might also exert a direct effect against colorectal carcinogenesis by inhibiting vascular endothelial growth factor production, thereby down-regulating angiogenesis, which is essential for tumor growth and invasion [8] . BCAAs also serve as key precursors of glutamine synthesis, which is a known intestinal trophic factor and is reported to protect cells from inflammation and oxidative stress [9] . To our knowledge, however, the association between BCAA and the risk of CRA, a precursor lesion of CRC, has not been investigated.
Here, we measured plasma concentrations of leucine, isoleucine and valine and evaluated their associations with the risk of CRA in a middle-aged and elderly Japanese population.
Materials and methods
The participants for the present study were selected from examinees who underwent magnifying colonoscopy with dye spreading as part of a cancer screening program provided by the Research Center for Cancer Prevention and Screening, National Cancer Center, Tokyo, Japan between February 2004 and 2005 [10] . Men (aged 50-79 years) and women (aged 40-79 years) undergoing total colonoscopy from the anus to the cecum and without a history of CRA, any malignant neoplasm, ulcerative colitis, Crohn's disease, familial adenomatous polyposis, carcinoid tumor or colectomy were considered eligible for inclusion in the study. During a 1-year period, 3212 examinees underwent total colonoscopy, among whom 2234 satisfied the above eligibility criteria and were considered for inclusion. Based on the pit pattern classification of colorectal lesions, 526 men and 256 women were found to have at least one or more adenomas and were included in the study as adenoma cases. Of the remaining 1452 individuals, 482 men and 721 women were found to be free of adenoma or other benign lesions (e.g. hyperplastic polyps, inflammatory polyps and diverticula) and were considered as potential controls. Because there were fewer potential controls than cases in males, all potential male controls were included. For female controls, these were frequency-matched to the cases by age (<50, 50-54, 55-59, 60-64 and !65 years) and screening period (first and second halves) and randomly selected in a 1:1 ratio. In total, we included 782 adenoma cases and 738 controls. The study protocol was approved by the institutional review board of the National Cancer Center, Tokyo, Japan.
All participants completed a self-administered questionnaire survey before the colonoscopic procedure. The questionnaire was designed to obtain demographic and lifestyle information, including information on smoking and drinking habit, weight and height at the time of examination, usual physical activity, medical history, family CRC history and reproductive history (for females). They were also encouraged to complete a 138-item food frequency questionnaire with pre-specified portion sizes and intake frequency categories.
Laboratory assays
Blood sample collection was mostly done a day before the colonoscopic screening procedure. Fasting venous blood was drawn into a vacutainer tube with ethylenediaminetetraacetic acid. These samples were then centrifuged to obtain the plasma and buffy coat layers, which were then stored at À80 C until analysis.
A 75-ml portion of plasma sample was added to 75 ml of APDSTAG TM Wako Amino Acids Internal Standard Mixture Solution (isotope-labeled amino acid) and 150 ml of acetonitrile (Merck Millipore, Tokyo, Japan). The solution was vortexed, and then centrifuged at 18 581 g for 10 min at 20 C. BCAA analysis was carried out using a UF-Amino Station (Shimadzu Corporation, Kyoto, Japan) equipped with degasser, a pump, autosampler, column oven and mass spectrometer. Separation was carried out on a Shim-pack UF-Amino column (100 mm Â 2.1 mm; 2 mm) (Shimadzu Corporation, Kyoto, Japan), and eluted with APDSTAG TM Wako Eluent and acetonitrile (Wako Pure Chemical Industries, Osaka, Japan). Amino Acid Analysis Reagent (for LC/MS) (APDSTAG TM ) and APDSTAG TM Wako Borate Buffer were prepared for the derivatization of amino acids. All assays were carried out at the Frontier Research Laboratories, Institute for Innovation, Ajinomoto Co., Inc. As quality control measurements, three duplicate samples from two subjects were interspersed with other samples in a blinded manner to laboratory personnel. The intra-assay and inter-assay coefficients of variation (CV) for all three components of BCAA were 4.8% or less, except for isoleucine in one sample for which the inter-assay CV was 8.5%.
Statistical analysis
All subjects were divided into quartile categories according to plasma BCAA values among the controls of each sex. An unconditional logistic regression model was used to estimate odds ratios (OR) and 95% confidence intervals (CI) of CRA according to quartile of plasma BCAA, with the lowest category as reference. The regression models were adjusted for age (continuous), screening period (first or second half), physical activity (MET-hours/day, quartile), cigarette smoking (never, 20, 21-40 and >40 pack-years), alcohol consumption (never, past, <150, 150-299, !300 g/week), family CRC history, diabetes mellitus history, nonsteroidal anti-inflammatory drug (NSAID) use, reproductive factors in females (age at menarche, menopausal status and hormone use) and energy-adjusted intakes of folate, fiber, isoflavone, red and processed meat, and body mass index (BMI, kg/m 2 ; all variables adjusted in continuous scale). Linear trends in the ORs of CRA were assessed by assigning ordinal values of 0-3 to the quartile categories of plasma BCAA. Interaction terms were created between indicator variables representing categories of leucine and of sex, BMI (<25 or !25 kg/m 2 ) and physical activity (in 2 groups by median cutoff), and their significance was statistically evaluated based on the likelihood ratio test with three degrees of freedom. A multinomial logistic regression model was applied to evaluate the association of leucine with adenoma site, size and location and to test for heterogeneity in the effects of leucine by adenoma characteristics. Two-sided P values of <0.05 were considered statistically significant. All statistical analyses were carried out using SAS version 9.3 (SAS Institute, Inc., Cary, NC). For this analysis, three participants without available plasma samples for measurement of BCAA concentration, 13 with missing information on covariates and 291 with a fasting time of 6 h at the time of sample collection were excluded, leaving a total of 629 adenoma cases and 584 controls in the analysis. Table 1 summarizes the selected characteristics of adenoma cases and controls by sex. In men, cases tended to be older, had higher BMI and a more frequent history of diabetes mellitus, and were less likely to use NSAIDs than controls. In women, cases were more likely to smoke and more frequently had a parental history of CRC than controls. The two groups of either sex showed no significant differences in terms of dietary intake factors or plasma BCAA concentrations.
Results
The multivariate-adjusted ORs (95% CIs) of CRA according to quartile categories of leucine, isoleucine, valine and total BCAAs are shown in Table 2 . We observed no clear association between plasma leucine concentration and the risk of CRA in the initial lifestyle and dietary factor-adjusted model. However, after additional adjustment for BMI, plasma leucine concentration was significantly inversely related with CRA. Similar albeit slightly weaker patterns of inverse association of CRA were also observed with valine and BCAA but not with isoleucine. In a further analysis in men and women separately, an inverse association with leucine, valine and BCAAs was clearly evident in men, but not in women. The interaction by sex was not significant, however (P interaction ¼ 0. When we reanalyzed the association of leucine in all populations according to adenoma site, size and number, the inverse association was limited to proximal and distal adenoma, but did not appear to differ by strata of adenoma size or number (supplementary Table S1 , available at Annals of Oncology online). We further evaluated the leucine/CRA association by subgroups of BMI and physical activity. Overall, the OR of CRA showed a decreasing trend with increasing quartiles of BCAA in both subgroups of BMI and physical activity, although the decrease in the magnitude of OR appeared to be stronger in lean (<25 kg/m 2 ) and physically active (! median) subgroups. However, the interaction effect was not significant for either BMI (P interaction ¼ 0.26) or physical activity (P interaction ¼ 0.96).
Discussion
In this study, we observed an inverse association between higher circulating concentrations of leucine, valine and total BCAA and CRA after adjusting for potential confounders, particularly BMI. This inverse association appeared to be clearly evident in men, but not in women, although there was no indication of a significant interaction effect by sex. Overall, our findings provide support for the hypothesis that BCAAs may have protective role in colorectal carcinogenesis.
The mechanisms underlying this possible association between BCAA and colorectal neoplasia are not clear. In a recent experimental study of azoxymethane-treated male obese and diabetic mice, Shimizu et al. reported that, compared with the control diet mice, mice fed a BCAA-supplemented diet developed significantly fewer aberrant crypt foci and b-catenin accumulated crypts, both of which are premalignant lesions of the colon [7] . In addition, the BCAA-supplemented mice had significantly lower expression of IGF-I receptor on the colonic mucosa, as well as lower serum levels of IGF-1, insulin and leptin than the control diet mice. These authors suggested that BCAA might inhibit the formation of colonic premalignant lesions and excessive cell proliferation in the colonic mucosa by improving insulin resistance and by inhibiting the activation of IGF-I receptor. These findings may support our present study. At present, evidence for the role of BCAAs in metabolic health is conflicting. In contrast to the favorable effects of supplemental/ dietary BCAA intake in improving glucose tolerance and insulin sensitivity [11, 12] , circulating concentrations of BCAA have been associated with altered glucose and insulin homeostasis [13] . In fact, higher plasma levels of BCAAs were associated with the risk of diabetes in a nested case-control study which included mostly overweight and obese individuals [13] . Other studies, which have been similarly conducted in mostly overweight and obese populations, have also shown positive correlations between circulating BCAAs and markers of insulin resistance [14, 15] . Although highly regulated within a small range in leaner subjects [16, 17] , circulating concentrations of BCAAs are elevated in obese subjects, possibly due to the reduced BCAA catabolic enzyme activity observed in increased adiposity conditions [16, 18] . It is therefore possible that higher circulating levels of BCAAs are linked to the characteristics of overweight and obese subjects (i.e. insulin resistance), and are thus associated with the development of diabetes. Of interest, circulating BCAA level was inversely correlated with HOMA-IR in a leaner Japanese population [19] . Similar to this observation in a Japanese population, our study also contained fairly lean subjects (median BMI of 23.3 kg/m 2 ). We therefore speculate that the altered correlation of BCAA with insulin resistance may be related to the differing effects of BCAA against colorectal neoplasia in a leaner population, although stratified analysis did not show an interaction by BMI in the present study. Hence, the association between BCAA and CRA requires comparisons between several populations having different BMIs.
Another interesting aspect of the present finding was that the significant inverse association between BCAA and CRA was clearly evident only after adjustment for BMI. Given that BMI, an established risk factor for CRA, tends to positively correlate with BCAA, one of the most likely reasons is that negative confounding by BMI might have led to underestimation of a protective effect of BCAA among those in higher BCAA levels without adjustment for BMI. Indeed, the mean BMI increased with increasing BCAA levels, at 21.6, 22.5, 23.7 and 24.2 kg/m 2 from the first to fourth quartiles, respectively (P 0.0001). As a plausible consequence, BMI adjustment moved the risk estimates away from the null, and thus made them more unbiased.
Recently, two metabolomics-based studies used prospectively collected plasma/serum samples to identify metabolites associated with CRC [20, 21] . The first study included 254 case-control pairs from the PLCO trial and reported an inverse association between leucyl-leucine and CRC, although the association did not reach statistical significance after multiple comparison adjustment [20] . The second study consisted of 937 case-cohort samples with 163 cases from the EPIC-Heidelberg cohort and reported a consistent association between lysophosphatidylcholines (C18:0 concentration) and CRC risk [21] . However, neither of these studies reported a measurable association with BCAA.
Major strengths of this study include the provision of total colonoscopy to all participants, large sample size, measurement of plasma amino acids, and adjustment for potential confounding factors. We limited all analyses to participants who had fasted for longer than 6 h at the time of blood sampling to remove concerns about higher BCAA values in the circulation from dietary load. In contrast, a major limitation of our study is its cross-sectional design, and the observed associations might have been due to reverse causality. As these lesions are generally asymptomatic, however, changes in dietary habits are less likely, and no clear effect of the presence of adenoma on BCAA concentration has been reported. Blood samples were obtained at a single point in time and BCAA levels were measured only once, and may have been subject to measurement error. However, a recent study showed acceptable within-person reproducibility (r ! 0.4) for the majority of the 22 amino acids evaluated [22] . Adenoma tissues lacked histological verification in our study. However, our preliminary survey reported the high accuracy of diagnosis by magnifying chromoendoscopy (90%), and any misclassification in case status is likely to be minimal. Although we adjusted for known or potential confounding factors in the multivariable models, residual or unmeasured confounding remains possible.
In summary, we found that a higher concentration of plasma BCAA, particularly leucine and valine, was inversely associated with the risk of CRA. Given the lack of prior evidence for a role of BCAA in colorectal carcinogenesis and the inherent limitations of our study design, additional studies are required to verify findings as well as to aid understanding of how BCAA metabolism influences colorectal pathogenesis in humans.
